Navigation Links
VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
Date:9/18/2013

MARIETTA, Ga., Sept. 18, 2013 /PRNewswire/ -- VIVEX BIOMEDICAL, INC., a biomaterials manufacturer and developer, announced today that it has successfully completed its first round of private equity financing.  The financing involved an over-subscribed offering of the Company's preferred stock, generating $7.6 million in start-up capital. 

Tracy Anderson, President and CEO of Vivex, said, "We are grateful to our shareholders and investors.  They have provided us capital to grow our rapidly expanding biosciences portfolio while allowing the executive team to focus on the strategic execution and day to day operations.  We are excited about the future of Vivex."

Start-up capital will be used to refine current and develop new products, expand its team, and identify and pursue strategic partnerships and other opportunities.  The company's patented flagship products, currently in development, include the MIAMI stem cell and mimetic pattern implants and other protected Intellectual Property.  The company's core biomaterials include demineralized bone matrix, sponge, allograft, and calcium phosphate products backed by a proprietary cleansing process that sustains bioactivity.

About VIVEX BIOMEDICAL, INC.

Vivex commenced operations in 2013 following a spin-off of the biomaterials division of Amendia, Inc., a Marietta, Georgia spinal implant manufacturer, and has since experienced rapid growth.  In support of the biologics-oriented platform, Vivex is developing a strategic portfolio of revolutionary interactive implants that nurture and guide the body's regenerative responses for accelerated healing while minimizing recuperation. The company's soon to be released flagship products range from bioresonant mimetic implants that encourage and enhance response from the body, to a revolutionary undifferentiated adult stem cell line that retains the multi-lineage potential to repair virtually any tissue type.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal security laws.  Forward-looking statements are only predictions and are not guarantees of performance.  You should not place undue reliance on any forward-looking statements.  

For more information, please visit the company's website at www.vivex.com or contact the company's General Counsel, Michael F. Rozmajzl, Esq., CPA., at 770.575.5221.  


'/>"/>
SOURCE VIVEX BIOMEDICAL, INC.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
2. Saladax Biomedical Announces Addition to Leadership Team
3. Funding Tomorrow's Biomedical Research: California Healthcare Institute Hosts Pipeline for Life, July 15
4. The Galien Foundation Celebrates Biomedical Innovation in Fourth Galien Forum
5. David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research
6. BioMedical Life Systems, Inc. Launches New FDA Cleared Non-Prescription TENS Device
7. Ondine Biomedical CEO Carolyn Cross Appointed Treasurer of International Photodynamic Association
8. Arteriocyte announces Launch of Compass Biomedical
9. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
10. Premier Biomedical CEO Interviewed by The Wall Street Transcript
11. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017 UCHealth ( Aurora, Colorado ... pulmonary nodule patient management. In addition to optimizing care ... on the lung, UCHealth looks to improve provider workflow ... Stephanie Brown, RN , Thoracic Nurse ... with an Excel spreadsheet, which was extremely arduous and ...
(Date:2/16/2017)... , Feb. 16, 2017  Windtree Therapeutics, Inc. ... focusing on developing aerosolized KL4 surfactant therapies for ... preclinical influenza study showed that aerosolized KL4 surfactant ... a well-established preclinical animal model. The Company believes ... body of evidence that supports the role of ...
(Date:2/15/2017)... (PRWEB) , ... February 15, 2017 , ... ... Posard, as President and Chief Commercial Officer with GenePeeks. Matt is a ... , GenePeeks is a computational genomics company focused on identifying inherited disease risk ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
Breaking Biology News(10 mins):